Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma

References

• Skin cancers: how common is skin cancer? Ultraviolet radiation and the INTERSUN Programme. Geneva: World Health Organization. [cited 2016 Apr 5]. Available from: http://www.who.int/uv/faq/skincancer/en/index1.html
   Google Scholar
• Korn EL, Liu PY, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol: Off J Am Soc Clin Oncol. 2008 Feb 1;26(4):527–534.
   PubMed Web of Science ®Google Scholar
• Haanen JB. Immunotherapy of melanoma. EJC Suppl: EJC: Off J EORTC, Eur Organiz Res Treat Cancer [et al]. 2013 Sep;11(2):97–105.
   PubMedGoogle Scholar
• Maio M. Melanoma as a model tumour for immuno-oncology. Ann Oncol: Off J Eur Soc Med Oncol /ESMO. 2012 Sep;23(Suppl 8):viii10–4.
   PubMed Web of Science ®Google Scholar
• Houghton AN, Gold JS, Blachere NE. Immunity against cancer: lessons learned from melanoma. Curr Opin Immunol. 2001 Apr;13(2):134–140.
   PubMed Web of Science ®Google Scholar
• Kalialis LV, Drzewiecki KT, Klyver H. Spontaneous regression of metastases from melanoma: review of the literature. Melanoma Res. 2009 Oct;19(5):275–282.
   PubMed Web of Science ®Google Scholar
• Kamposioras K, Pentheroudakis G, Pectasides D, et al. Malignant melanoma of unknown primary site. To make the long story short. A systematic review of the literature. Crit Rev Oncol Hematol. 2011 May;78(2):112–126.
   PubMed Web of Science ®Google Scholar
• Jakob JA, Bassett RL Jr, Ng CS, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 2012 Aug 15;118(16):4014–4023.
   PubMed Web of Science ®Google Scholar
• Teulings HE, Limpens J, Jansen SN, et al. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol: Off J Am Soc Clin Oncol. 2015 Mar 1;33(7):773–781.
   PubMed Web of Science ®Google Scholar
• Byrne KT, Turk MJ. New perspectives on the role of vitiligo in immune responses to melanoma. Oncotarget. 2011 Sep;2(9):684–694.
   PubMed Web of Science ®Google Scholar
• Oble DA, Loewe R, Yu P, et al. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun. 2009;9:3.
   PubMedGoogle Scholar
• Hussein MR. Tumour-infiltrating lymphocytes and melanoma tumorigenesis: an insight. Br J Dermatol. 2005 Jul;153(1):18–21.
   PubMed Web of Science ®Google Scholar
• Erdag G, Schaefer JT, Smolkin ME, et al. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res. 2012 Mar 1;72(5):1070–1080.
   PubMed Web of Science ®Google Scholar
• Garraway LA, Lander ES. Lessons from the cancer genome. Cell. 2013 Mar 28;153(1):17–37.
   PubMed Web of Science ®Google Scholar
• Escors D. Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy. New J Sci. 2014 Jan 5;2014:1–25.
   Google Scholar
• Hodi FS, Mihm MC, Soiffer RJ, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A. [2003 Apr 15];100(8):4712–4717.
   PubMed Web of Science ®Google Scholar
• FDA approves Keytruda for advanced melanoma: first PD-1 blocking drug to receive agency approval. FDA News Release. Silver Spring (MD): U.S. Food and Drug Administration. [cited 2016 Feb 9]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm412802.htm
   Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012 Apr;12(4):252–264.
   PubMed Web of Science ®Google Scholar
• Patnaik A, Kang SP, Rasco D, et al. Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res: Off J Am Assoc Cancer Res. 2015 Oct 1;21(19):4286–4293.
   PubMed Web of Science ®Google Scholar
• Center for Drug Evaluation and Research, Application Number: 125514Orig1s000. Pharmacology Review(s). Silver Spring (MD): U.S. Food and Drug Administration. [cited 2016 May 2]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125514Orig1s000PharmR.pdf
   Google Scholar
• Bruhns P, Iannascoli B, England P, et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood. 2009 Apr 16;113(16):3716–3725.
   PubMed Web of Science ®Google Scholar
• Jefferis R, Lund J. Interaction sites on human IgG-Fc for FcgammaR: current models. Immunol Lett. 2002 Jun 3;82(1–2):57–65.
   PubMed Web of Science ®Google Scholar
• Radaev S, Sun P. Recognition of immunoglobulins by Fcgamma receptors. Mol Immunol. 2002 May;38(14):1073–1083.
   PubMed Web of Science ®Google Scholar
• Scapin G, Yang X, Prosise WW, et al. Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab. Nat Struct Mol Biol. 2015 Dec;22(12):953–958.
   PubMed Web of Science ®Google Scholar
• Arnold JN, Wormald MR, Sim RB, et al. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol. 2007;25:21–50.
   PubMed Web of Science ®Google Scholar
• Lux A, Nimmerjahn F. Impact of differential glycosylation on IgG activity. Adv Exp Med Biol. 2011;780:113–124.
   PubMed Web of Science ®Google Scholar
• Quast I, Lünemann JD. Fc glycan-modulated immunoglobulin G effector functions. J Clin Immunol. 2014 Jul;34(Suppl 1):S51–55.
   PubMed Web of Science ®Google Scholar
• Van Der Neut Kolfschoten M, Schuurman J, Losen M, et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science (New York, NY). 2007 Sep 14;317(5844):1554–1557.
   PubMed Web of Science ®Google Scholar
• Sathish JG, Johnson KG, Fuller KJ, et al. Constitutive association of SHP-1 with leukocyte-associated Ig-like receptor-1 in human T cells. J Immunol (Baltimore, Md: 1950). 2001 Feb 1;166(3):1763–1770.
   PubMed Web of Science ®Google Scholar
• Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704.
   PubMed Web of Science ®Google Scholar
• Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev. 2008 Aug;224:166–182.
   PubMed Web of Science ®Google Scholar
• Guleria I, Khosroshahi A, Ansari MJ, et al. A critical role for the programmed death ligand 1 in fetomaternal tolerance. J Exp Med. 2005 Jul 18;202(2):231–237.
   PubMed Web of Science ®Google Scholar
• Sharpe AH, Wherry EJ, Ahmed R, et al. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007 Mar;8(3):239–245.
   PubMed Web of Science ®Google Scholar
• KEYTRUDA® (pembrolizumab) Prescribing Information. Kenilworth (NJ): Merck Sharp & Dohme Corp. [cited 2016 May 2]. Available from: http://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf
   Google Scholar
• Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001). Bethesda (MD): ClinicalTrialsgov. U.S. National Institutes of Health. [cited 2016 Apr 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT01295827
   Google Scholar
• Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013 Jul 11;369(2):134–144.
   PubMed Web of Science ®Google Scholar
• Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014 Sep 20;384(9948):1109–1117.
   PubMed Web of Science ®Google Scholar
• Wolford JE, Tewari KS. US FDA oncology drug approvals in 2014. Future Oncol. 2015;11(13):1931–1945.
   PubMed Web of Science ®Google Scholar
• Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (P08719/KEYNOTE-002). Bethesda (MD): ClinicalTrialsgov. U.S. National Institutes of Health. [cited 2016 Apr 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT01704287?term=KEYNOTE-002&rank=1
   Google Scholar
• Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015 Aug;16(8):908–918.
   PubMed Web of Science ®Google Scholar
• Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006). Bethesda (MD): ClinicalTrialsgov. U.S. National Institutes of Health. [cited 2016 Apr 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT01866319?term=KEYNOTE-006&rank=1
   Google Scholar
• Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015 Jun 25;372(26):2521–2532.
   PubMed Web of Science ®Google Scholar
• Pembrolizumab label updated with new clinical trial information. Approved Drugs. Silver Spring (MD): U.S. Food and Drug Administration. [cited 2016 Feb 9]. Available from: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm478493.htm
   Google Scholar
• Wolchok JD, Hodi FS, Weber JS, et al. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci. 2013;1291:1–13.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res: Off J Am Assoc Cancer Res. 2009 Dec 1;15(23):7412–7420.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012 Jun 28;366(26):2443–2454.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012 Jun 28;366(26):2455–2465.
   PubMed Web of Science ®Google Scholar